Akari Therapeutics Plc
(NASDAQ: AKTX)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $3.18 | Change: +0.08 | %Change: +2.64% | Volume: 2,374 |
Open: | $ 3.23 | Volume: | 2,374 | |
---|---|---|---|---|
High: | $ 3.31 | Yield(%) | 0.00 | |
Low: | $ 3.10 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 24.56M | |
EPS ($) | -3.86 | Shares Out: | 7.92M |
% Price Change (last 4 weeks): | 60.62 |
---|---|
% Price Change (last 13 weeks): | 105.30 |
% Price Change (last 26 weeks): | 7.02 |
% Price Change (last 52 weeks): | -6.40 |
% Price Change (year to date): | -0.64 |
Return on Equity (%): | -1281.64 |
---|---|
Return on Assets (%): | -110.06 |
Return on Invested Capital (%): | -1000.46 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $2.06 |
---|---|
200-day Moving Average: | $2.57 |
Avg. Daily Vol. (last 50 days): | 27,865 |
Avg. Daily Vol. (last 200 days): | 15,928 |
52-wk high: | $5.50 |
52-wk low: | $1.08 |
Bid: | $3.04 |
Ask: | $3.91 |
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.
|
Akari Therapeutics Plc
22 Boston Wharf Road 7th Floor Boston MA 02210 Phone: 1.929.274.7510 Fax: n/a http://www.akaritx.com |
Earnings (1year) ($): | n/a |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | -0.03 |
Cash Flow ($): | -1.51 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | n/a |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 0.95 |
---|---|
Current Ratio (x): | 0.95 |
LT Debt/Equity (x): | n/a |
Total Debt/Equity (x): | n/a |